- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07939139
Shadow-Mode Evaluation of an AI Assistant for Multidisciplinary Tumor Boards (OnkoBot)
OnkoBot: Prospective Shadow-Mode Evaluation of a Locally Operated, Source-Grounded Large Language Model System for Drafting Multidisciplinary Tumor Board Recommendations
This study tests whether an artificial intelligence (AI) system that drafts tumor board recommendations performs as well on new cases as it did on archived cases. The system runs in shadow mode at three multidisciplinary tumor boards of TUM University Hospital rechts der Isar. For each case it drafts a recommendation before the board meets. The board does not see the draft, and the draft has no influence on patient care. After the meeting, each draft is compared with the board decision. The agreement rate is then compared with the rate measured on archived decisions of the same boards.
Aperçu de l'étude
Statut
Intervention / Traitement
Description détaillée
The system is a locally operated large language model (LLM) pipeline with retrieval-augmented generation. Its input is the case as presented to the board, with diagnosis, course, question and all patient documents dated before the board date. It retrieves guideline recommendations (Onkopedia and AWMF S3 guidelines in the version in force on the board date), laboratory values, precedent cases from the board archive and PubMed abstracts published before the board date. It then drafts a recommendation with justification. Each statement of the draft is linked to a verbatim quote from its source. All models run on local GPU servers of the hospital with no data retention beyond the immediate analysis, and no patient data are sent to external providers.
The study includes the hematology board, the orthopedics and sarcoma board and the head and neck board. For each case registered for a session, the system drafts a recommendation after the pre-board documents are pulled and before the session starts. Board members do not see the drafts. The decision pipeline (generator Gemma-4-31B at temperature 0) is frozen and versioned for the study period. The study uses routine clinical data only. Patients are not contacted, and no study-specific procedures are performed.
The draft is compared with the consensus decision in the board report. An LLM judge (GLM-5.3-Flash, majority of three votes) assigns both texts to one of seven decision categories: systemic therapy, surgery, radiotherapy, watch and wait, further diagnostics, best supportive care and referral to the molecular tumor board. It also scores agreement in substance from 0 to 3 and records the direction of any disagreement. The judge was validated against clinician ratings on a sealed test set. The same prompt version is used to score the prospective cases and the retrospective reference sample, separately from any output that clinicians see.
The retrospective reference is the evaluation sample of archived decisions of the same three boards (about 2,000 cases, one per patient, drawn with a fixed seed and stratified by time). Patients who also appear in the prospective cohort are removed from the reference. The primary analysis tests non-inferiority of the prospective category match rate against the retrospective rate, pooled over the three boards, with a margin of 7.5 percentage points and a one-sided alpha of 0.025. The variance is cluster-robust for board sessions. A case without a draft counts as not concordant. Per-board results are reported descriptively with 95% confidence intervals. An exploratory component evaluates a trial-matching engine that proposes recruiting clinical trials per case.
In a subset of 30 to 50 cases per board, physicians rate the system draft against the board decision. This subset tests whether the agreement between judge and clinicians, measured retrospectively, also holds prospectively.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Lisa Adams, MD
- Numéro de téléphone: +49 89 4150 1084
- E-mail: lisa.adams@tum.de
Sauvegarde des contacts de l'étude
- Nom: Keno Bressem, MD
- E-mail: keno.bressem@tum.de
Lieux d'étude
-
-
Bavaria
-
Munich, Bavaria, Allemagne, 81675
- Pas encore de recrutement
- TUM University Hospital rechts der Isar
-
Munich, Bavaria, Allemagne
- Recrutement
- TUM Klinikum rechts der Isar
-
Contact:
- Lisa Adams, Prof.
- Numéro de téléphone: +49 89 4140-1084
- E-mail: lisa.adams@tum.de
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
All cases registered for the hematology, orthopedics and sarcoma, and head and neck tumor boards of TUM University Hospital rechts der Isar during the study period. One case is one patient presentation on one board date.
La description
Inclusion Criteria:
- Case registered for a session of a participating tumor board (hematology, orthopedics and sarcoma, head and neck) of TUM University Hospital rechts der Isar during the study period
- Board registration and pre-board patient documents available before the session starts
Exclusion Criteria:
- Case not discussed at the session, defined as no board report with a consensus decision for that date (deferred or withdrawn registrations)
- Session without a shadow run of the system
Excluded cases are counted and reported by reason.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Hematology board
Consecutive cases presented at the hematology tumor board of TUM University Hospital rechts der Isar. |
A locally operated, source-grounded large language model system drafts a tumor board recommendation with justification and verified citations for each case before the board meeting. The draft is not shown to the board and does not influence patient care. |
|
Orthopedics and sarcoma board
Consecutive cases presented at the orthopedics and sarcoma tumor board of TUM University Hospital rechts der Isar. |
A locally operated, source-grounded large language model system drafts a tumor board recommendation with justification and verified citations for each case before the board meeting. The draft is not shown to the board and does not influence patient care. |
|
Head and neck board
Consecutive cases presented at the head and neck tumor board of TUM University Hospital rechts der Isar. |
A locally operated, source-grounded large language model system drafts a tumor board recommendation with justification and verified citations for each case before the board meeting. The draft is not shown to the board and does not influence patient care. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of Cases With Category Match Between System Draft and Board Decision
Délai: Each case is assessed once, after the board report of its session is available; analysis after accrual is complete (anticipated January 2027)
|
Proportion of discussed cases in which the system draft and the board consensus decision fall into the same of seven decision categories (systemic therapy, surgery, radiotherapy, watch and wait, further diagnostics, best supportive care, referral to the molecular tumor board). Overlap counts where either side carries a second category. Assessed by a pre-specified LLM judge (GLM-5.3-Flash, prompt V3, majority of three votes), pooled over the three boards. Tested for non-inferiority against the rate of the same system and judge on the retrospective reference sample of the same boards, margin 7.5 percentage points, one-sided alpha 0.025. |
Each case is assessed once, after the board report of its session is available; analysis after accrual is complete (anticipated January 2027)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of Cases Rated Concordant or Partially Concordant
Délai: After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
|
Category match with a substance score of at least 1 of 3 (concordant requires at least 2 of 3 on a primary-category match, 3 of 3 where only second categories overlap). Non-inferiority versus retrospective reference, margin 7.5 percentage points, tested after the primary outcome (hierarchical testing). |
After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
|
|
Proportion of Cases Rated Concordant, Partially Concordant and Not Concordant
Délai: After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
|
Proportion of cases rated concordant, partially concordant and not concordant by the LLM judge. |
After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
|
|
Proportion of Cases With Category Match per Board
Délai: After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
|
Category match and concordant or partially concordant per board, with 95% confidence intervals, descriptive. |
After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
|
|
Proportion of Discordant Cases by Direction of Disagreement
Délai: After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
|
Among cases without category match, proportion in which the draft is more conservative, more aggressive or a different modality than the board decision. |
After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
|
|
Proportion of Cases With Category Match as Rated by Clinicians
Délai: Within 3 months after the board session
|
In 30 to 50 cases per board, agreement between draft and board decision as rated by physicians who did not attend the session, and agreement between judge and clinicians on category match (percentage agreement, Cohen's kappa). |
Within 3 months after the board session
|
|
Proportion of Citations Verified Word for Word Against Their Source
Délai: At draft generation, before the board session
|
Proportion of citations per case that verify word for word against their source, and proportion of cases in which every citation verifies. |
At draft generation, before the board session
|
|
Proportion of Cases With a Draft Completed Before the Board Session
Délai: At draft generation, before the board session
|
Proportion of cases with a draft completed before the session starts, and generation time per case in minutes. |
At draft generation, before the board session
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Clinical Trials Shortlisted per Case by the Trial-Matching Engine
Délai: At draft generation, before the board session
|
Number of trials shortlisted per case, proportion recruiting on the board date, rule-based error rate (wrong disease, line of therapy, setting or status) and clinician screening verdicts where given. |
At draft generation, before the board session
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Lisa Adams, MD, Technical University of Munich
- Chercheur principal: Krischan Braitsch, MD, Technical University of Munich
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- ONKOBOT-SHADOW-01
- KK6050201BM5 (Autre subvention/numéro de financement: Central Innovation Programme for SMEs (ZIM), German Federal Ministry for Economic Affairs)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Individual participant data are routine clinical records that may not leave the hospital under the ethics approval and data protection concept. Aggregate results and the analysis code will be published.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .